Novavax has reported that data from a pivotal Phase III trial of its vaccine candidate, NVX–CoV2373, in the UK showed an efficacy of 96.4% against mild, moderate and severe disease caused by the original Covid-19 strain. A protein-based vaccine candidate, NVX-CoV2373 is engineered from the genetic sequence of SARS-CoV-2. The Phase III trial enrolled over […]